Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant PD-1-based combination strategies after non-MPR to neoadjuvant immunotherapy in resected NSCLC
ChiCTR2400091455Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab, IBI310, IBI363 and LM-108 in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: 2-year disease-free survival rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
sintilimabIBI310IBI363LM-108
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400091455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091455.